STOCK TITAN
  1. Home
  2. News
  3. FRLN

Freeline Therapeutics Holdings plc - FRLN STOCK NEWS

Welcome to our dedicated news page for Freeline Therapeutics Holdings plc (Ticker: FRLN), a resource for investors and traders seeking the latest updates and insights on Freeline Therapeutics Holdings plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Freeline Therapeutics Holdings plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Freeline Therapeutics Holdings plc's position in the market.

News
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Rhea-AI Summary
Freeline Therapeutics will present new data on its Gaucher and Parkinson’s disease programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. The company will discuss clinical data from its Gaucher disease program, highlighting the potential of FLT201 gene therapy for better efficacy with a one-time treatment. Additionally, Freeline will share new data from its Parkinson’s disease research program, focusing on leveraging the enhanced stability of their rationally engineered GCase enzyme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Acquisition of Freeline by Syncona Becomes Effective
Rhea-AI Summary
Freeline Therapeutics Holdings plc (FRLN) has been acquired by Syncona Ltd through a sanctioned scheme of arrangement, with shareholders entitled to receive $0.433333 per share or $6.50 per ADS. The acquisition has led to the de-listing of Freeline ADSs from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Freeline Shareholders Approve Acquisition by Syncona
Rhea-AI Summary
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) shareholders approve Bidco's acquisition proposal by Syncona Ltd for $6.50 per ADS in cash. The Acquisition is set to be effective on February 20, 2024, pending court approval and other closing conditions. ADSs expected to be delisted from Nasdaq on February 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
acquisition
News
Syncona to Acquire Freeline Therapeutics
Rhea-AI Summary
Freeline Therapeutics Holdings plc (FRLN) has agreed to be acquired by a portfolio company of Syncona Ltd (SYNC) for $6.50 per American Depositary Share (ADS), representing a 51% premium over the closing price prior to the announcement of Syncona's initial proposal on October 18. The acquisition is subject to the approval of Freeline's minority shareholders and is expected to close in the first quarter of 2024. Syncona will also provide $15 million in convertible debt financing to support Freeline's near-term capital needs and advancement of its gene therapy candidate in Gaucher disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.21%
Tags
acquisition
-
News
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Rhea-AI Summary
Freeline Therapeutics announces positive clinical data for its gene therapy candidate FLT201 for Gaucher disease. The data shows a substantial reduction in lyso-Gb1 levels, a biomarker of clinical response, in the first patient treated with FLT201. Increases in plasma GCase activity and normalization of cellular GCase levels continue to be observed in the first two patients. FLT201 is well-tolerated with no serious adverse events. The Phase 1/2 GALILEO-1 trial is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
clinical trial
-
News
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
Rhea-AI Summary
Freeline Therapeutics reports positive initial safety, tolerability, and enzyme activity data for its gene therapy candidate FLT201 in Gaucher disease. FLT201 demonstrated robust increases in plasma GCase enzyme activity, with up to a 700-fold increase over baseline. Leukocyte GCase activity also normalized in both patients, indicating cellular uptake from plasma. The therapy was well tolerated with no serious adverse events. The company plans to treat a third patient at the same dose to gather more data before deciding on further dosing. A webcast presentation discussing the results will be held today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
clinical trial
News
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Freeline Therapeutics completes dosing in the first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease. Initial clinical data expected in Q3 2023. Company extends research program for GBA1-linked Parkinson's disease. Financial results for Q2 2023 reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.85%
Tags
earnings
-
News
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
conferences earnings
-
News
Freeline to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) will be participating in two upcoming investor conferences in August. CEO Michael Parini will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 7. The management will also participate in one-on-one meetings at the Wedbush Healthcare Conference from August 8-9 in New York City. A live webcast of the BTIG fireside chat will be available on Freeline's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences
News
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
Rhea-AI Summary
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) will host a virtual Key Opinion Leader (KOL) event on August 1, 2023, to discuss its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1. The event will feature Gaucher disease expert, Dr. Reena Sharma, and the Freeline leadership team will provide a corporate overview and outline the clinical progress of FLT201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
conferences
Stock FRLN logo
Freeline Therapeutics Holdings plc

Nasdaq:FRLN

FRLN Rankings

N/A Ranked by Market Cap
#4705 Ranked by Stock Gains
N/A Ranked by Dividends

FRLN Stock Data

28.24M
26.80M
1.1%
45.88%
0.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
Stevenage

About FRLN

freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com